2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-147751
    APJ receptor agonist 6 1965244-85-2 98%
    APJ receptor agonist 6 (compound 9) is a potent APJ (apelin receptor) agonist, with Ki of 1.3 μM. APJ receptor agonist 6 has EC50 values of 0.070 , 0.097, and 0.063 μM for calcium, cAMP, and β-arrestin, respectively.
    APJ receptor agonist 6
  • HY-147910
    Carpro-AM1 2499489-76-6 98%
    Carpro-AM1 is a dual-acting FAAH/substrate-selective COX inhibitor with an IC50 value of 94 nM for FAAH.
    Carpro-AM1
  • HY-148000
    sEH inhibitor-6 1205963-04-7 98%
    sEH inhibitor-6 (Compound 3g) is a soluble epoxide hydrolase (sEH) inhibitor with an IC50 of 0.5 nM.
    sEH inhibitor-6
  • HY-148144
    Clobutinol 14860-49-2 98%
    Clobutinol is a compound that has anti-tussive effects. Clobutinol affects heart rate and blood pressure, it can be used for cough related research.
    Clobutinol
  • HY-148292
    C16-Sphingosine-1-phosphate 709026-60-8 98%
    C16-Sphingosine-1-phosphate is a derivative of Sphingosine-1-phosphate and also an endogenous ligand for the EDG/S1P receptor. C16-Sphingosine-1-phosphate can be used in the research of angiogenesis, inflammation, and cardiovascular diseases.
    C16-Sphingosine-1-phosphate
  • HY-148312
    Sirtuin modulator 4 327104-77-8 98%
    Sirtuin modulator 4 (compound 12) is a sirtuin modulator. Sirtuin modulator 4 shows inhibitory effect to SIRT1 with an EC50 value of 51-100 μM. Sirtuin modulator 4 may be used for the research of increasing the lifespan of a cell, and preventing a wide variety of diseases and disorders including, for example, diabetes, obesity, neurodegenerative diseases, cardiovascular diseases, inflammation and cancer.
    Sirtuin modulator 4
  • HY-14839A
    Evatanepag sodium 223490-49-1 98%
    Evatanepag sodium is a non-prostanoid, potent and selective EP2 receptor agonist. Evatanepag sodium can induce local bone formation in vivo. Evatanepag sodium can be used in the research of fractures, bone defects, asthma.
    Evatanepag sodium
  • HY-148475
    (R)-SEMBL 1443449-07-7 98%
    (R)-SEMBL (compound 1B) is a potent NF-κB inhibitor. (R)-SEMBL can be used for the research of cancer, inflammation, autoimmune diseases, diabetes and diabetes complications, infections, cardiovascular disease and defective reperfusion injury.
    (R)-SEMBL
  • HY-148480
    Nrf2 activator-6 2728780-74-1 98%
    Nrf2 activator-6, a tetrahydroisoquinoline compound, is a Nrf2 activator. Nrf2 activator-6 has an IC50 of 5 nM for inhibiting the Kelch domain-Nrf2 interaction (WO2021214470A1; Example 4).
    Nrf2 activator-6
  • HY-148524
    β2AR/M-receptor agonist-1 2230520-62-2 98%
    β2AR/M-receptor agonist-1 (example 131) is a muscarinic antagonist and β2 adrenoceptor agonist (MABA). β2AR/M-receptor agonist-1 shows potency to β2 adrenoceptor with an EC50 value of 9.2 nM. β2AR/M-receptor agonist-1 also has potency to muscarinic receptor with a Ki value of 30.2 nM. β2AR/M-receptor agonist-1 shows MABA potency with an EC50 value of 4.0 nM.
    β2AR/M-receptor agonist-1
  • HY-148525
    PF-4348235 1017857-38-3 98%
    β2AR/M-receptor agonist-2 (compound 15) is a muscarinic antagonist and β2 adrenoceptor agonist (MABA). β2AR/M-receptor agonist-2 shows potency to β2 adrenoceptor with an EC50 value of 3.7 nM. β2AR/M-receptor agonist-2 also has potency to human cloned M3 receptor with a Ki value of 0.73 nM. β2AR/M-receptor agonist-2 is a potent bronchodilator, it can be used for the research of chronic obstructive pulmonary disease (COPD).
    PF-4348235
  • HY-148573
    sEH inhibitor-14 2890221-26-6 98%
    sEH inhibitor-14 (compound 33) is a benzoxazolone-5-urea analogue. In addition, sEH inhibitor-14 is a soluble Epoxide Hydrolase (sEH) inhibitor (IC50=0.39 nM).
    sEH inhibitor-14
  • HY-148625
    PDE9-IN-2 917089-10-2 98%
    PDE9-IN-2 (compound 6) is a PDE9 inhibitor that improves heart failure.
    PDE9-IN-2
  • HY-148651
    CDK2-IN-15 1219915-83-9 98%
    CDK2-IN-15 (Compound 19) is an inhibitor of CDK2 with an IC50 of 2.9 μM. CDK2-IN-15 can be used for cancer research.
    CDK2-IN-15
  • HY-148670
    Pulmonary arterial hypertension agent-1 1201082-00-9 98%
    Pulmonary arterial hypertension agent-1 (example 15) is a pulmonary arterial hypertension agent. Pulmonary arterial hypertension agent-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Pulmonary arterial hypertension agent-1
  • HY-148837
    GT19630 2883535-99-5 98%
    PROTAC c-Myc degrader-1 (Compound A153) is a multiple target protein degrader (PROTAC). PROTAC c-Myc degrader-1 effective degrades c-MYC, CK1α, GSPT1 and IKZF1/2/3 proteins in a variety of tumor cells. PROTAC c-Myc degrader-1 can be used for c-Myc high expression related disease research, such as cancer, cardiovascular and cerebrovascular diseases, and viral infection (Pink: c-Myc ligand (HY-168685); Blue: E3 ligase ligand (HY-W093472); Black: linker (HY-W015808)).
    GT19630
  • HY-149094
    Neuroprotective agent 1 2344786-13-4 98%
    Neuroprotective agent 1 (2), a promising neuroprotective agent for the study of ischemic stroke, shows promising neuroprotective activity with the EC50 value of 16.07 μM in the model of glutamate-induced excitotoxicity and 19.30 μM in the model of H2O2-induced oxidative damage.
    Neuroprotective agent 1
  • HY-149101
    Riboxin 86-04-4 98%
    Riboxin (IDP), an orally active purine derivative-hypoxanthine rlboside, has antihypoxic and antihyperthermic activity. Riboxin also has an antiarrhythmic action in cats, rabbits, and mice with cardiac rhythm disorders induced by Ouabain. Riboxin protects animals against the noxious effects of γ-irradiation.
    Riboxin
  • HY-149173
    CDK-IN-11 2376876-87-6 98%
    CDK-IN-11 is a heterocyclic compound that has an action of promoting cardiomyocyte maturation.
    CDK-IN-11
  • HY-149260
    HIF-1 inhibitor-5 98%
    HIF-1 inhibitor-5 (Compound 16e) is a potent HIF-1 inhibitor with an IC50 of 2.38 μM. HIF-1 inhibitor-5 possesses anti-angiogenic potential.
    HIF-1 inhibitor-5
Cat. No. Product Name / Synonyms Application Reactivity